Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481347 | 1.00 | FNTA (0.44) | FNTAFNTBMDM2NPC1RAB9A | |
| SCHEMBL6481344 | 1.00 | FNTA (0.44) | FNTAFNTBMDM2NPC1RAB9A | |
| SCHEMBL6481519 | 0.89 | NPC1 (0.49) | FNTAFNTBMDM2NPC1RAB9A | |
| SCHEMBL6481522 | 0.89 | NPC1 (0.49) | FNTAFNTBMDM2NPC1RAB9A | |
| SCHEMBL6481526 | 0.89 | NPC1 (0.49) | FNTAFNTBMDM2NPC1RAB9A | |
| SCHEMBL6758440 | 0.88 | ATM (0.46) | ATM | |
| SCHEMBL4383512 | 0.88 | ATM (0.46) | ATM | |
| SCHEMBL6758441 | 0.88 | ATM (0.46) | ATM | |
| SCHEMBL6758461 | 0.86 | ATM (0.43) | MDM2ATM | |
| SCHEMBL6758456 | 0.86 | ATM (0.43) | MDM2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838439-B2 | Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-6514952-B1 | Hydantoin derivatives as inhibitors of leucocyte adhesion and as VLA-4 antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| US-6034238-A | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENT | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-03-07 | — | — | US | disclosed |
| US-5998447-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT AG (DE) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, ICAM1, ITGB4 | FNTA 1463/4885FNTB 1906/4885MDM2 4077/4885 |
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | FNTA 1683/4885FNTB 1294/4885MDM2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.